HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.2%

Neg 0% Neu 89.2% Pos 0%

HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $7 price target.